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Oscar C. Yeh, PhD,* and R. Bruce Martin, PhD* Abstract: Using a computational model of bone adaptation, we investigated the 
long-term ability of bisphosphonates to minimize proximal bone loss that is 
associated with stress shielding in the tibia after long-stemmed total knee 
arthroplasty (TKA). When invoking bisphosphonate effects, the remodeling activity 
was suppressed, and the resorption size was reduced. Compared with the untreated 
simulation, bisphosphonate slowed the rate of bone loss after TKA (42% reduction 
in bone loss at 1 year). Activating the drug 3 months before the surgery reversed 
bone loss associated with the reduction in such activities as walking, but it did not 
provide any substantial benefit in the long-term. Late bisphosphonate treatment did 
not reverse the bone loss that occurred 3.5 years after TKA, although it preserved 
3% of bone normally lost without treatment. Key words: stress shielding, TKA, 
bisphosphonate, finite element analysis, press fit. Implant failure in total joint arthroplasty may be 
prevented when adequate fixation of the implant 
components is achieved after surgery and when 
this fixation is maintained over the long-term [1]. 
Although mechanically stiff stems with a large 
diameter and extensive porous coating (which 
facilitates bony ingrowth) provide the initial sta­
bility and fixation, these attributes, when applied 
to femoral prostheses in total hip arthroplasty 
(THA), have been found to be associated with 
more pronounced periprosthetic bone resorption 
[2]. Moreover, this bone loss compromises long-term fixation, and loosening of the prosthesis may 
occur [3]. 
Bone loss after total joint arthroplasty occurs, in 
part, because the relatively stiffer implants reduce 
the physiological loading of the contiguous bone, 
leading to disuse bone remodeling. The majority of 
such bone loss typically occurs within the first 
year after total joint arthroplasty and has been 
observed by serial x-ray absorptiometry in the 
proximal femur after THA [4-8]. Similar findings 
have been observed after total knee arthroplasty 
(TKA) in the distal femur [9-11] as well as in the 
proximal tibia [12-15]. Through implant design 
(eg, peg or stem), material selection (eg, cobalt 
chrome alloy or titanium alloy), and fixation tech­
nique (eg, press fit or cement), attempts have been 
made to minimize this phenomenon. Although 
such efforts have improved the longevity of total 
joint arthroplasty, mechanical-related bone loss 
(ie, stress shielding) has not been prevented, and 
multiple revision surgeries are still an eventual­
ity, especially for young patients (younger than 
50 years) with a reconstructed joint who are 
typically more active and live longer than older 
patients with a joint arthroplasty. 
It is well documented that the drug alendronate 
increases bone mineral density (BMD) in the 
femoral neck and trochanter of postmenopausal 
women with osteoporosis [16-25]. This bisphosph­
onate drug may be equally effective in preventing 
or reversing bone loss associated with stress shield­
ing. There is the possibility, however, that bisphos­
phonates may disrupt the important process of 
bone apposition to implant surfaces, which ensures 
adequate fixation, because bisphosphonates can 
inhibit mineralization (especially at high dosages). 
Allaying such a concern, Frenkel et al [26] and 
Mochida et al [27] found that alendronate did not 
inhibit bony integration to various titanium sur­
faces and hydroxyapatite-coated femoral stems, 
respectively, in a dog model. 
Whether bisphosphonates can prevent bone loss 
associated with total joint arthroplasty as they do 
for postmenopausal bone has been explored in 
both animals and human beings. Besides stress 
shielding, bone loss may result from the cellular 
response (ie, macrophages) to wear debris. There­
fore, using a rat model of particulate-induced 
osteolysis, alendronate was studied and found to 
prevent or reverse bone loss in the tibia [28] and 
the femur [29] when polyethylene particles were 
injected near the implant. Because there was more 
bone around the implant in the group subjected to 
particulates and alendronate, although osteoclasts 
were present, than in the nontreated group (im­
plant only), Millett et al [28] concluded that 
alendronate reduces osteoclastic activity, thereby 
reducing bone resorption and preserving bone. 
Venesmaa et al [30] and Soininvaara et al [31] 
investigated whether alendronate could prevent 
periprosthetic bone loss in the human femur after 
THA and TKA, respectively. Each prospective 
randomized trial found that the alendronate­
treated group had a significantly smaller decrease 
in BMD than the calcium only–treated group after 
6 months to 1 year of total joint arthroplasty. 
Similarly, Wilkinson et al [32] found that a single 
dose of another bisphosphonate drug, pamidronate, 
significantly reduced proximal bone loss in the 
femur by 26 weeks after THA compared with a 
control. Moreover, the drug was not associated with 
more adverse events (eg, cardiac failure and diar­
rhea) than normally occur after THA without 
bisphosphonate treatment. 
Although these studies suggest that bisphospho­
nates can reduce bone loss after total joint arthro­
plasty, the question still remains whether this effect 
can be maintained over the long term. To investi­  
gate this in a relatively short time frame, bisphosph­
onate effects were simulated here with existing 
computational models of bone remodeling devel­
oped for the tibia with long-stemmed TKA [33] and 
for bisphosphonate treatment [34]. Additional 
questions that were investigated with this theoret­
ical model were (1) would bisphosphonates given 
3 months before surgery provide better protection 
against bone loss than those given immediately 
after surgery? (2) do bisphosphonates recover bone 
that has already been lost to stress shielding? and 
(3) what are the relative contributions of suppres­
sion of remodeling activity and reduction in resorp­
tion area to minimizing bone loss? 
Materials and Methods 
Bone Adaptation Model 
Changes in bone mass after long-stemmed TKA 
with and without bisphosphonate treatment were 
simulated using a finite element model of the tibia 
coupled with a theoretical model of bone remodel­
ing [33]. In the theoretical model, which is des­
cribed by Hazelwood et al [35], bone loss associated 
with disuse was assumed to occur when a me­
chanical stimulus (U) dropped below a disuse 
threshold (U0). In each element of bone, the 
mechanical stimulus was estimated from the prin­
cipal strains (e) of 3 daily loading activities and 
their respective loading frequency (RL): 
3 
U ¼ e 4RLi ð1Þ 
i¼1 
X 
When the mechanical stimulus is less than the 
disuse threshold, the activation frequency (Ac.f) of 
basic multicellular units (BMUs), the teams of cells 
that remove and then replenish packets of bone, 
were increased in both cortical and trabecular 
bone. The disuse-related increase in remodeling 
activity resulted in bone loss caused by an increase 
in the number of resorption sites. Also, if the 
porosity was greater than 20% and the bone was in 
a state of disuse, bone formation decreased relative 
to resorption in each BMU, thereby causing 
negative bone turnover or disuse remodeling: 
U 
Formation ¼ 0:5 � Resorption 1 þ ð2Þ 
U0 
In other words, the bone balance ratio (forma­
tion per resorption) at the BMU level was less than 
1 when bone was in state of disuse. The model 
tracked changes in the amount of bone occupying a 
representative area within each element via the 
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Fig. 1. Comparing distribution of BAF in the nonoper­
ated tibial bone at steady state (A) to that for TKA at 700 
days postoperative TKA reveals a greater loss of bone 
when bisphosphonates are not simulated (B) than when 
their effects are included immediately postoperative (C). through the resorption, reversal, and formation 
periods. Bone mass was thus calculated as bone 
area per total area or bone area fraction (BAF). Bone Remodeling Simulations 
Starting with a homogeneous material state 
throughout the tibia and applying physiological 
joint reaction forces, the bone mass distribution 
was allowed to evolve until each variable of the 
model reached a steady state as described in a 
previous study [33]. Briefly, the joint reaction force 
was evenly distributed normal to each condyle 
surface in 1 situation, and then the other situations 
had medial-biased (70%/30%) or lateral-biased 
(30%/70%) loading with a 58 tilt to account for 
lateral or medial ground reaction forces. The model 
calculated tibial surface strains in the physiological 
range, as measured by Burr et al [36]. Once a 
steady state was achieved, the tibia model exhibited 
a normal anatomic distribution of cortical and 
cancellous bone that was used as the starting point 
for the current study (Fig. 1A). Table 1. Material Properties for the C
Material Young’s modulus (MPa) Poisson’s 
PMMA 2150 0.46 
UHMWPE 2300 0.25 
Titanium 79000 0.36 
Cortical 23400 (BAF)5.74 0.30 
Trabecular 14300 (BAF)1.33 0.30 
Abbreviation: UHMWPE, ultrahigh molecular weight polyethylene.  
From the equilibrium, normal condition, the 
forces and loading frequencies acting on the model 
were reduced by 10% and 22%, respectively, to 
simulate loss of loading activity caused by osteoar­
thritic pain [37]. Bone remodeling was then 
allowed to evolve for another 200 days. We did 
not include any aging or disease effects on the 
material behavior of bone (ie, the relationship 
between BAF and modulus did not change). 
A long-stem version of TKA was selected so that 
the effectiveness of bisphosphonate in preserving 
bone mass would be investigated in a severe case of 
stress shielding. We set the TKA components, 
comprised of a 16 � 120 mm press fit, titanium 
alloy stem with a cemented tibial tray, and ultra­
high molecular weight polyethylene insert, to their 
respective material properties (Table 1) and ran 
implant simulations for the succeeding 6.5 years 
without bisphosphonate treatment or with treat­
ment starting on either the day of TKA, 3 months 
before TKA, or 3.5 years after TKA. Joint reaction 
forces, but not loading frequency, were returned to 
normal after 100 days. Bone loss was quantified 
below the tibial tray as percent change from the 
intact tibial BAF after reduction in loading activity. 
Bisphosphonate Effects 
The 2 main antiresorptive actions of bisphosph­
onate are the inhibition of BMU activation fre­
quency and reduction in erosion by the BMU [40]. 
Because these actions occur when the bisphosph­
onate comes in contact with an osteoclast and 
suppression is greatest in regions of high remodel­
ing activity [41], the potency of suppressing 
activation frequency was a function of the number 
of resorbing BMUs. 
�ss�N :Rs:BMU P ¼ Pmax 1 � e ð3Þ 
where Pmax is the maximum suppression coeffi­
cient, ss is the rate of suppression coefficient, and 
N.Rs.BMU is the number of resorbing BMUs. 
Bisphosphonate treatment was simulated in the omponents of TKA and for Bone 
ratio Location Reference 
Below tray Lewis et al [38] 
Tibial insert Lewis et al [38] 
Tray and stem Lewis et al [38] 
BAF N0.8; Fig. 2A Turner et al [39] 
BAF V0.8; Fig. 2A Turner et al [39] 
 
Fig. 2. The rate of bone loss after TKA below the 
tibial tray is slower when bisphosphonate effects are 
simulated than without treatment. Abbreviation: BP, 
bisphosphonate. model by suppressing BMU activation frequency by 
the percentage of P, and then independent of 
activation frequency suppression, the normal re­
sorption by BMUs was reduced by 3/13th, 
corresponding to the reduction in erosion depth 
observed by Chavassieux et al [42]. In a previous 
study by Nyman et al [34], these antiresorptive 
actions were invoked in a representative volume of 
postmenopausal trabecular bone. With a maximum 
suppression coefficient of 1.0, a rate of suppression 
coefficient of 5, and a reduction in the erosion 
depth by 3/13th, the simulation predicted an 
increase in bone mass similar to that observed by 
dual-energy x-ray absorptiometry over 7 years in 
the spines of postmenopausal women who were 
treated daily with 10 mg of alendronate [24]. More 
specifically, the simulation matched the clinically 
observed 4% increase in BMD over the first 
6 months of treatment. It also matched the 
decreasing rate of BMD increase between 6 months 
and 7 years of treatment. Therefore, these coef­
ficients were invoked when simulating bisphosph­
onate effects in the TKA model. 
In 2 additional simulations of bisphosphonate 
treatment starting on the day of TKA, (a) the rate of 
suppression coefficient was increased to 20 without 
changing the reduction in resorption and (b) 
resorption was reduced by 2/7th without changing 
the rate of suppression. The former action effec­
tively increases the suppression of activation fre­
quency of new BMUs, whereas the latter further 
reduces the size of resorption space created by 
BMUs. This sensitivity analysis was done to inves­
tigate the contributions of activation suppression 
and bone balance, respectively, on inhibiting bone 
loss associated with stress shielding (ie, mechani­
cally induced disuse bone remodeling). To eluci­
date the underlying mechanism of bone loss in the 
model, mechanical stimulus, activation frequency, 
and bone balance were recorded (as an average 
within the region of interest) over time for 
each simulation. Results 
Compared with the untreated simulation, 
bisphosphonate treatment preserved bone mass 
after TKA (Fig. 2). Furthermore, it prevented the 
thinning of the cortices that can occur with TKA. Its 
antiresorptive effects, however, did not completely 
prevent proximal bone loss associated with stress 
shielding but slowed the progression of loss (Fig. 2). 
One year after TKA, there was an average of 42.0% 
less bone loss below the tibial tray with bisphosph-onate treatment given the day of surgery than 
without bisphosphonate treatment. Activating the 
drug 3 months before TKA reversed some of the 
bone loss associated with the reduction in loading 
activity that typically occurs with osteoarthritic 
knees, but it did not provide any substantial benefit 
in the long term. Bisphosphonate given 3.5 years 
after TKA did not reverse the bone loss that 
occurred up to that time after surgery, although it 
slowed the rate of loss (saved 3% of bone normally 
lost at 6.5 years). Increasing activation frequency 
suppression potency of a bisphosphonate drug had 
a greater effect than reducing the resorption size 
(ie, improving the bone balance) in preserving 
bone over the long term. 
Decreasing the loading activity lowered the 
mechanical stimulus below the disuse threshold 
and subsequently caused bone loss (Fig. 2). Reduc­
ing bone resorption by invoking bisphosphonate 
treatment before TKA caused positive bone turn­
over within the BMU (ie, more bone was added 
than removed as shown in Fig. 3), and bone loss 
was temporarily reversed (dotted line in Fig. 2). 
When the long-stemmed TKA was simulated at 6 
months after reduction in loading, bone loss in the 
model resumed, despite the pharmacological sup­
pression of bone resorption and the return of 
normal joint reaction forces. In the model of 
long-stem TKA without drug intervention, signifi­
cant stress shielding had 2 consequences: (a) 
increased remodeling activity introduced porosity 
and (b) bone formation in each BMU decreased 
relative to resorption. This elevated rate of remod­
eling subsided over time as the reduction of bone 
Fig. 3. Bone balance, the ratio of formation area (FAr) 
to resorption area (Rs.Ar) is less than 1 because the state 
of disuse caused by the TKA overrides the increase 
provided by bisphosphonate unless the drug is given 
3.5 years postoperatively. mass increased the strain. With bisphosphonate 
treatment, the stimulation of disuse remodeling by 
TKA was suppressed. However, there was still a 
decrease in bone formation, and although the drug 
decreased BMU erosion depth, formation remained 
less than resorption (Fig. 3). In other words, the 
drug did not overcome the consequences of stress 
shielding but delayed them. Discussion 
The objective of simulating the antiresorptive 
action of bisphosphonate in a hypothetical bone 
adaptation model of long-stem TKA was to inves­
tigate (1) whether the drug minimizes bone loss 
associated with stress shielding over the long term, 
(2) whether giving the drug in advance of surgery 
provided any additional benefit, and (3) whether 
the drug could recover bone mass that had already 
been lost because of stress shielding. Secondary 
objectives included investigating the relative con­
tributions of activation frequency suppression and 
resorption size reduction in minimizing bone loss 
and understanding the underlying mechanisms of 
bone loss. 
Bisphosphonate treatment in the present study 
minimized bone loss after TKA, reducing bone loss 
by almost one half below the tibial tray during the 
6.5-year period. Bone loss was not completely 
stopped because (a) remodeling was suppressed 
but not completely blocked and (b) a disuse state 
or stress shielding was prolonged compared with TKA without treatment. To clarify, without anti-
resorptive action, bone strains increased after their 
initial decrease as bone stiffness was lost to stress 
shielding. Subsequently, the mechanical stimulus 
returned to the threshold level, and the bone 
balance approached one (Fig. 3) as the rate of 
bone loss slowed. With bisphosphonate treatment, 
however, the preservation of bone kept the strain 
on bone at a reduced level. Therefore, despite the 
reduction in bone resorption relative to normal 
bone formation, the disuse state imposed a nega­
tive bone turnover (ie, resorption was greater 
than formation). 
Despite an improvement in the bone balance 
ratio (ie, increased positive bone turnover per 
BMU) when bisphosphonate treatment was given 
3.5 years after TKA, there was no significant gain in 
bone. This was because of the rather low remodel­
ing activity occurring at the time of treatment. 
There were too few BMUs to cause perceptible 
increase in bone mass. For a gain to occur, a 
pharmacological agent would likely need to pro­
mote bone formation in addition to suppressing 
bone resorption. 
In the present model, invoking a more sensitive 
suppression of remodeling activity (a rate of 
suppression coefficient of 20 instead of 5) caused 
fewer number of resorbing BMUs, whereas invok­
ing a greater reduction in resorption by osteoclasts 
(71.4% of normal formation instead of 76.9% of 
normal formation) caused a more positive bone 
turnover per BMU. Interestingly, the model pre­
dicted that increasing the potency of a bisphosph­
onate drug further reduces the amount of bone 
formed at the BMU level (compare the dotted line 
to the triangle line in Fig. 3) but still reduces the 
amount of bone loss overall. This was because of 
the fact that there were fewer BMUs to remove 
bone with high suppression. Based on the predic­
tions of the present bone remodeling simulations, 
greater potency of remodeling suppression should 
be a higher priority than greater potency of 
resorption reduction when designing bisphospho­
nate drugs for TKA. 
To the best of our knowledge, the effect of 
bisphosphonates on tibial bone density after TKA 
has not been studied. Moreover, there are no 
clinical studies that have measured bone loss below 
the tibial tray for long-stemmed TKA. Nonetheless, 
there are 3 clinical observations that support the 
suitability of the present analytical model. First, 
several studies observed that the majority of bone 
loss in the tibia after TKA occurs in the first year 
and diminishes thereafter [12,14,15,43]. This trend 
was predicted by the model when simulating TKA 
without bisphosphonate treatment (Fig. 2). Sec­
ond, the predicted thinning of the cortices by the 
model (Fig. 1B) has been observed clinically after 
TKA by Seitz et al [44]. Third, Karbowski et al [12] 
reported that a tibial endoprosthesis with stem 
length of 40 mm caused an average 9.26% decrease 
in tibial bone density below the tray after 9 months 
of TKA, and Regner et al [15] reported a tibial 
endoprosthesis with stem length of 60 mm that 
caused an average 22% decrease in tibial bone 
density in a similar region. From a mechanical 
viewpoint, bone loss increases with an increase in 
stem length [45]. Thus, a greater bone loss than 
found clinically for shorter stems would occur for a 
120-mm stem as the model predicts. Lastly, bone 
loss did occur in the short term after THA or 
TKA when patients were given bisphosphonates 
[30-32], and it was significantly less than in 
patients who were not treated with the drug. 
The model also predicted much less bone loss for 
treated TKA compared with TKAs without the 
actions of bisphosphonate. 
The present findings come from a hypothetical 
model of TKA bone adaptation, so they should 
be interpreted in light of the limitations of the 
model. Such limitations included those related to 
2-dimensional finite element models: plane strain 
assumptions, exclusion of out-of-plane forces, sim­
plification of geometry, and idealization of material 
behavior. Nonetheless, the model predicts the 
morphological characteristics of the tibia (cortices 
at the diaphysis, medullary canal, and cancellous 
bone in metaphysis) given the few hypothetical 
loading activities. One limitation in the simulation 
of bisphosphonate treatment is the absence of the 
contribution of secondary mineralization to bone 
mass. Because bisphosphonates slow remodeling 
activity, there is more time for bone to mineralize, 
which increases mass, before being replaced with 
fresh osteoid [46]. This is an additive effect suggest­
ing that the present study overpredicts bone loss 
with the drug. Another possible limitation is the 
independence between the fixed reduction in 
resorption size and suppression of remodeling 
activity. Unlike activation frequency suppression, 
resorption reduction was not a function of the 
number of resorbing BMUs (ie, as the presence of 
osteoclasts increased, the resorbing efficiency or 
BMU life span did not decrease proportionally). The 
consequence of this is unclear because resorption 
size affects both porosity (hence, stiffness of bone) 
and microdamage removal (hence, the demand for 
activation frequency). 
The results of the present study suggest that 
bisphosphonate treatment starting on the day of TKA may slow the progression of bone loss 
associated with stress shielding. Preserving bone 
mass over the long term would reduce the likeli­
hood of aseptic loosening, a common cause for 
revision. There appears to be no advantage of 
giving the drug in advance to prevent bone loss 
because of a reduction in loading activity, and 
starting the administration of the drug several years 
after surgery may only provide modest benefits. 
Because of known side effects and a long half-life 
(N10 years), routine use of bisphosphonate in TKA 
would require a long-term clinical study. Acknowledgments 
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